Christopher D Conrady1, Marissa Larochelle1, Paula Pecen2, Alan Palestine2, Akbar Shakoor1, Ajay Singh3. 1. Department of Ophthalmology, John A. Moran Eye Center, University of Utah, Salt Lake City, UT, 84112, USA. 2. Department of Ophthalmology, University of Colorado School of Medicine, Aurora, CO, 80045, USA. 3. Department of Ophthalmology, University of Kansas School of Medicine, Kansas City, KS, 66160, USA. asingh@discovervision.com.
Abstract
PURPOSE: Checkpoint inhibitors are now a common treatment modality for metastatic cancer. In this manuscript, we describe the clinical features and management of autoimmune non-infectious uveitis induced by this class of drugs. METHODS: Seven patients undergoing checkpoint inhibitor treatment for metastatic cancer from uveitis practices at three tertiary referral centers. RESULTS: All seven patients developed various severities of ocular inflammatory disease while taking checkpoint inhibitors for metastatic disease. CONCLUSIONS: Checkpoint inhibitors may induce autoimmune uveitis. Ocular complaints should prompt an early evaluation by an ophthalmologist.
PURPOSE: Checkpoint inhibitors are now a common treatment modality for metastatic cancer. In this manuscript, we describe the clinical features and management of autoimmune non-infectious uveitis induced by this class of drugs. METHODS: Seven patients undergoing checkpoint inhibitor treatment for metastatic cancer from uveitis practices at three tertiary referral centers. RESULTS: All seven patients developed various severities of ocular inflammatory disease while taking checkpoint inhibitors for metastatic disease. CONCLUSIONS: Checkpoint inhibitors may induce autoimmune uveitis. Ocular complaints should prompt an early evaluation by an ophthalmologist.
Entities:
Keywords:
Autoimmune uveitis; Checkpoint inhibitors; Metastatic cancer
Authors: K M Lee; E Chuang; M Griffin; R Khattri; D K Hong; W Zhang; D Straus; L E Samelson; C B Thompson; J A Bluestone Journal: Science Date: 1998-12-18 Impact factor: 47.728
Authors: H Nishimura; T Okazaki; Y Tanaka; K Nakatani; M Hara; A Matsumori; S Sasayama; A Mizoguchi; H Hiai; N Minato; T Honjo Journal: Science Date: 2001-01-12 Impact factor: 47.728
Authors: Elisabetta Contardi; Giulio L Palmisano; Pier Luigi Tazzari; Alberto M Martelli; Federica Falà; Marina Fabbi; Tomohiro Kato; Enrico Lucarelli; Davide Donati; Letizia Polito; Andrea Bolognesi; Francesca Ricci; Sandra Salvi; Vittoria Gargaglione; Stefano Mantero; Marco Alberghini; Giovanni Battista Ferrara; Maria Pia Pistillo Journal: Int J Cancer Date: 2005-11-20 Impact factor: 7.396
Authors: P Waterhouse; J M Penninger; E Timms; A Wakeham; A Shahinian; K P Lee; C B Thompson; H Griesser; T W Mak Journal: Science Date: 1995-11-10 Impact factor: 47.728
Authors: Leisha A Emens; S Lindsey Davis; Scott C N Oliver; Christopher H Lieu; Ashvini Reddy; Sharon Solomon; Lingmin He; Roland Morley; Marcella Fassò; Andrea Pirzkall; Hina Patel; Carol O'Hear; Daniela Ferrara Journal: JAMA Ophthalmol Date: 2019-01-01 Impact factor: 7.389
Authors: Natalie Wolkow; Frederick A Jakobiec; Amir H Afrogheh; Sara I Pai; William C Faquin Journal: Am J Ophthalmol Date: 2020-07-28 Impact factor: 5.488